Active	Status	Sponsor type	Region	Phase	Filter
8 Active 0 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Shen, Peng
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2	Recruiting	3	366	RoW	RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda	RemeGen Co., Ltd.	Breast Cancer	06/24	12/24
HER2CLIMB-02, NCT03975647 / 2019-005017-39: A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer Jan 2024 - Dec 2024: From HER2CLIMB-02 trial for breast cancer Jan 2022 - Dec 2022 : Completion of enrollment of HER2CLIMB-02 trial in combination with Kadcyla for breast cancer	Active, not recruiting	3	466	Europe, Canada, Japan, US, RoW	tucatinib, ONT-380, placebo, T-DM1, Kadcyla	Seagen Inc., Seagen Inc., Seattle Genetics, Inc., Seagen Inc	HER2-positive Breast Cancer	06/23	10/27
TQB3616-II-01, NCT04773418: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer	Recruiting	2	120	RoW	TQB3616 capsules, Fulvestrant injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	HR-positive, HER2-negative Advanced Breast Cancer	01/23	01/23
TQB3616-II-01, NCT04796623: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer	Recruiting	2	120	RoW	TQB3616 capsules, Fulvestrant injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	HR-positive, HER2-negative Advanced Breast Cancer	01/23	01/23
CRITICALLY, NCT05919056: Cardiovascular Risk Assessment and Dynamic Monitoring-based Prevention Trial	Recruiting	N/A	22032	RoW	Frequent and automatic cardiovascular risk assessment, Dynamic risk monitoring, Regular GP visits	Peking University, Yinzhou District Center for Disease Control and Prevention	Cardiovascular Diseases	07/28	07/28
TANG, Xun
PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis	Suspended	2	279	Europe, US, RoW	zetomipzomib, KZR-616, placebo, matching placebo	Kezar Life Sciences, Inc.	Lupus Nephritis	05/26	07/26
CRITICALLY, NCT05919056: Cardiovascular Risk Assessment and Dynamic Monitoring-based Prevention Trial	Recruiting	N/A	22032	RoW	Frequent and automatic cardiovascular risk assessment, Dynamic risk monitoring, Regular GP visits	Peking University, Yinzhou District Center for Disease Control and Prevention	Cardiovascular Diseases	07/28	07/28
GAO, Pei
CRITICALLY, NCT05919056: Cardiovascular Risk Assessment and Dynamic Monitoring-based Prevention Trial	Recruiting	N/A	22032	RoW	Frequent and automatic cardiovascular risk assessment, Dynamic risk monitoring, Regular GP visits	Peking University, Yinzhou District Center for Disease Control and Prevention	Cardiovascular Diseases	07/28	07/28